NOT financial advice - seek advice from a professional for your specific situation

    TaxKilnUK tax guidance
    TaxKilnUK tax guidance

    Patent Box

    Patent Box gives Ltd Cos an EFFECTIVE 10% CORPORATION TAX RATE on qualifying profits arising from patented inventions, vs the standard 25% main rate (or 19% SPR / 26.5% marginal). The relief operates as an ADDITIONAL DEDUCTION within the CT computation, reducing taxable profits so the effective rate on patent income lands at 10%. Election within 2 years of end of accounting period, applies prospectively only. Since July 2016 (Finance Act 2016), all new Patent Box claims use the MODIFIED NEXUS APPROACH, linking the amount of relief to the proportion of qualifying R&D carried out DIRECTLY by the company or by unconnected third-party subcontractors. The nexus fraction = (D + S1) × 1.3 ÷ (D + S1 + S2 + A), where D = in-house R&D, S1 = unconnected-party R&D, S2 = connected-party R&D, A = acquired qualifying IP. The 1.3 uplift rewards in-house + unconnected R&D; acquired IP + connected-party R&D reduce the fraction + the corresponding portion of profits eligible for the 10% rate.

    Last reviewed:

    Guidance, not advice. We explain the rules, we don't assess your situation. Always seek financial or tax advice from your accountant, or contact HMRC. Read our editorial scope →

    What this relief is, in plain English

    Patent Box is the UK's flagship innovation-incentive at the income side of the IP lifecycle. R&D Tax Credits subsidise the CREATION of innovation (15-27% credit on costs); Patent Box subsidises the COMMERCIAL EXPLOITATION of the resulting IP (effective 10% CT rate on profits). The combination is designed to make the UK an attractive location for IP-intensive businesses across the full lifecycle, research, patent filing, commercialisation, ongoing royalty income. The relief is generous in headline terms, 10% effective CT vs 25% main rate is a 60% reduction in the tax rate on patent-derived profits. But the mechanics are complex enough that many eligible companies don't claim it. Key barriers: (1) Patent grant process, need an actual granted patent (UK IPO, EPO, or specified EEA), not just a patent application. (2) Election + 2-year window, must elect within 2 years of end of accounting period; missed elections can't be retroactively rescued. (3) Modified nexus tracking, must document R&D cost composition (in-house D, unconnected S1, connected S2, acquired A) from inception of the patent project. (4) Income allocation, must allocate revenue streams to specific patents + calculate the patent-attributable portion of overall trading profit. (5) Specialist tax adviser support typically required, beyond DIY-CT600 territory. For companies where the relief is workable + the patent income is substantial, Patent Box is one of the highest-value UK Corporation Tax reliefs available. Pharmaceuticals, biotech, advanced engineering, specialist manufacturing, software-with-patentable-algorithms are the typical user populations.

    How it works

    10% effective rate via additional deduction

    Patent Box doesn't directly apply a 10% rate, it gives an ADDITIONAL CT DEDUCTION calculated to reduce the effective rate on qualifying patent income to 10%. Formula: Additional deduction = Relevant IP income × (Main CT rate - 10%) ÷ Main CT rate. At 25% main rate: Additional deduction = 60% of relevant IP income. The deduction reduces taxable profits → CT bill calculated on reduced profits → effective rate on the IP-attributable portion lands at 10%. Mechanic preserves the relief across changes in headline CT rate.

    Modified nexus fraction limits relief proportion

    Nexus fraction = (D + S1) × 1.3 ÷ (D + S1 + S2 + A), capped at 1. D = in-house R&D costs (staff, consumables, EPWs); S1 = R&D subcontracted to UNCONNECTED third parties; S2 = R&D subcontracted to CONNECTED persons (group companies); A = expenditure on ACQUIRING qualifying IP (purchased, not developed). The 1.3 uplift rewards in-house + unconnected-party R&D. Maximum relief when all R&D is in-house or unconnected (fraction = 1). Acquired IP + connected-party R&D dilute the fraction + reduce the relief proportion. Track R&D categorisation from project inception.

    Qualifying patents + qualifying IP income

    Qualifying patents: granted by UK IPO, EPO, or specified EEA patent authorities. Pending applications don't qualify until grant (though pre-grant income can sometimes be swept in via specific provisions). Qualifying IP income: sales of patented products (full selling price); licensing fees + royalties; infringement damages; proceeds from patent disposals; embedded patent income (notional allocation where patent is incorporated in product). Income attributable to non-patent factors (brand, marketing, distribution) excluded, must apportion.

    Election within 2 years of end of accounting period

    Election must be made within 2 years of the END of the accounting period for which it is to apply, prospective only. Cannot retroactively claim beyond the 2-year window. Election applies to ALL qualifying IP held, can't pick which patents to elect for. Once elected, regime applies until you elect OUT (which then creates 5-year lockout from re-electing in). Most companies elect in the first year of qualifying patent income. Documentation requirements substantial: R&D cost tracking, revenue attribution, nexus calculations per IP. Specialist tax adviser usually required.

    Who qualifies

    Interactions with other reliefs

    R&D Tax Credits (Merged Scheme + ERIS)

    Complementary, not mutually exclusive. R&D Tax Credits during the R&D investment phase (15-27% of qualifying expenditure as credit). Patent Box during the commercial-IP phase (10% effective CT rate on qualifying patent income). Same qualifying R&D expenditure feeds both: as cost basis for R&D Tax Credit calculation + as D / S1 inputs to modified nexus fraction. Strong R&D Tax Credit history = strong nexus fraction = full Patent Box relief on resulting IP profits.

    Creative Industry Tax Reliefs (AVEC / VGEC)

    Different IP types. Patent Box covers patent-derived income only, patents granted by UK/EPO/EEA authorities. Creative Industry reliefs cover film, TV, animation, video games via AVEC + VGEC mechanics. Companies producing patent-protected creative works (rare but possible, e.g. proprietary game engine technology) might access both regimes across different income streams.

    Corporation Tax Marginal Relief

    Patent Box deduction reduces taxable profits BEFORE marginal relief calculation. A company with £180,000 profits (in the marginal band) + £60,000 of qualifying patent income electing Patent Box: 60% × £60,000 = £36,000 additional deduction → taxable profits drop to £144,000 → still in marginal band. Combined relief value: Patent Box mechanic gives effective 10% on the £60,000 patent income (vs ~24% effective via marginal relief without Patent Box), saving £8,400 in CT.

    Substantial Shareholdings Exemption (SSE)

    SSE exempts CGT on disposal of qualifying subsidiary shares. Where a Patent-Box-using subsidiary is later sold, SSE can apply to exempt the gain, preserving the full value of the IP-developed business at exit. The two reliefs operate at different lifecycle stages: Patent Box during commercial operation; SSE at corporate exit.

    Common mistakes + audit triggers

    Worked example

    Hiroshi, Cambridge - Director of biotech Ltd Co with newly-granted patent + early commercial revenue (2025/26)

    Hiroshi's Cambridge biotech Ltd Co developed a novel diagnostic assay over 2021-2024 (£800,000 R&D spend, all in-house D = £800k; S1/S2/A = £0). Patent granted by UK IPO Q3 2025. First commercial royalties + licensing fees flowing from Q4 2025. 2025/26 accounting period: total trading profits £400,000, of which £180,000 attributable to patent-derived income (licence fees + initial product sales).

    Calculation: **Step 1: Nexus fraction calculation.** D = £800,000 (in-house R&D); S1 = 0; S2 = 0; A = 0. Nexus fraction = (D + S1) × 1.3 ÷ (D + S1 + S2 + A) = (£800k × 1.3) ÷ £800k = 1.3. Capped at 1.0. **Nexus fraction = 1.0** → 100% of qualifying patent income eligible for Patent Box. **Step 2: Identify qualifying patent income.** Licence fees received: £80,000. Product sales (patented diagnostic): £100,000. Total relevant IP income: £180,000. **Step 3: Calculate Patent Box additional deduction.** Additional deduction = Relevant IP income × (Main CT rate - 10%) ÷ Main CT rate = £180,000 × (25% - 10%) ÷ 25% = £180,000 × 15% ÷ 25% = £180,000 × 0.6 = **£108,000 additional deduction** **Step 4: Recalculated CT.** Without Patent Box: profits £400,000 × 25% = £100,000 CT (above marginal band, main rate). With Patent Box: profits reduce to £400,000 - £108,000 = £292,000. New CT at 25%: £292,000 × 25% = **£73,000**. Tax saving from Patent Box: £100,000 - £73,000 = **£27,000**. **Effective CT on the £180,000 patent income**: CT attributable to patent income (without relief): £180,000 × 25% = £45,000. CT attributable to patent income (with relief): £45,000 - £27,000 = £18,000. Effective rate: £18,000 / £180,000 = **10%** ✓ (Patent Box mechanic works as designed). **Step 5: Combined R&D Tax Credit + Patent Box value.** During 2021-2024 R&D phase: £800,000 qualifying R&D spend. - Under old SME scheme (pre-April 2024): 86% enhancement × loss-making payable credit 14.5% ≈ £100,000-£130,000 in R&D Tax Credit relief. - From Patent Box 2025/26 onwards: £27,000+/year (depending on patent income volume). - Combined IP lifecycle relief over 10 years: potentially £400,000-£500,000+ on an £800,000 R&D investment that generated a successful commercial patent. **Step 6: Election filing.** Must file Patent Box election with HMRC by 31 March 2028 (2 years from end of 2025/26 accounting period). Election applies prospectively from 2025/26 onwards. Documentation: nexus fraction calculation, qualifying patent details (granted UK IPO + EPO/EEA authorities if any), revenue attribution to patent vs non-patent factors, accountancy + specialist tax adviser engagement. Adviser fees for Patent Box first-year election typically £5,000-£15,000 depending on complexity, pays for itself many times over on substantial patent income.

    Statute reference: Corporation Tax Act 2010 + Finance Act 2016 (modified nexus) CTA 2010 Part 8A (ss.357A-357GE) + FA 2016 Sch.9. HMRC manual: CIRD200000 onwards.

    Frequently asked questions

    What happens if I miss the Self Assessment deadline?+
    The Self Assessment deadline is 31 January (online filing) for the previous tax year. Miss it and HMRC apply an automatic £100 penalty. Beyond that: £10 per day from 3 months late (capped at £900), 5% of tax due at 6 months late, and another 5% at 12 months late, under Schedule 55 of the Taxes Management Act 1970. If you have a genuine reason (serious illness, bereavement, technical issue with HMRC's systems) you can appeal with evidence; HMRC accepts reasonable excuse appeals in most genuine cases.
    Do I need an accountant or can I file Self Assessment myself?+
    Legally you can file Self Assessment yourself via gov.uk for free, most simple sole-trader returns (single income source, basic expenses) are realistic to self-file. An accountant adds real value when: your trading profit is above £40,000 (extraction-strategy decisions matter), you have multiple income streams (PAYE + self-employment + property + dividends), you've crossed the £90,000 VAT threshold, you're considering incorporation, or you have an HMRC enquiry. Expect to pay £400-£1,500/year for a typical sole-trader accountant; the cost is itself a deductible expense.
    How do payments on account work?+
    When your Self Assessment tax bill exceeds £1,000 for the first time, HMRC requires payments on account toward NEXT year's tax. Half the current bill is due 31 January (alongside the current bill); the other half is due 31 July. So your first January after crossing the threshold can hit with a double-bill: last year's balance + first payment on account. Adjust via Form SA303 if you expect next year's income to drop substantially. Payments on account don't apply if more than 80% of your tax is collected via PAYE.
    What counts as qualifying patent income for Patent Box?+
    Five main categories: (1) **Sales of patented products**: entire selling price of a product covered by a qualifying patent. (2) **Licensing fees**: royalties + licence payments received for granting others rights to use the patented invention. (3) **Infringement damages + compensation**: receipts from patent litigation enforcing the patent. (4) **Proceeds from patent disposals**: selling or otherwise disposing of the patent itself. (5) **Embedded patent income**: where a patent is INCORPORATED in a product but not the main commercial feature, a notional allocation of profit attributable to the patented component qualifies. Qualifying patents are granted by UK IPO, European Patent Office (EPO), or specified EEA patent authorities. Pending patent applications don't qualify until grant (though pre-grant income can be retroactively swept in via specific provisions once the patent grants).
    How does the modified nexus approach affect my relief?+
    The modified nexus fraction directly limits the proportion of qualifying patent income eligible for the 10% rate. **If all R&D was done in-house** (D dominant, S2 + A near zero): fraction approaches 1 (capped at 1) → full Patent Box relief on all qualifying patent income. **If most R&D was acquired** (A dominant): fraction approaches 0 → very limited Patent Box benefit on the patent income, even though it's qualifying income. **If R&D was largely subcontracted to UNCONNECTED parties** (S1 dominant): fraction approaches 1 (still high) → near-full relief, because the 1.3 uplift on (D + S1) preserves the calculation. The mechanic deliberately rewards companies doing their own R&D + penalises pure-acquisition IP strategies. Track R&D costs by category from inception of the patent project to maximise nexus fraction documentation.
    Can I claim R&D Tax Credits AND Patent Box on the same project?+
    Yes, they're designed to be COMPLEMENTARY, not mutually exclusive. R&D Tax Credits (Merged Scheme RDEC or ERIS) reward the COST of R&D during the development phase (15-27% of qualifying expenditure as credit). Patent Box rewards the INCOME from successfully commercialised IP once a patent is granted (10% effective CT rate). The two regimes operate at different points in the lifecycle: R&D Tax Credits during the loss-making development phase; Patent Box during the profitable commercialisation phase. Same R&D expenditure that fed R&D Tax Credit calculations ALSO feeds the modified nexus fraction (D + S1), so doing your own R&D + claiming R&D Tax Credits during development sets you up for full Patent Box relief on subsequent IP profits. The TaxKiln playbook for IP-intensive companies: claim R&D throughout R&D years → file patent applications → wait for grant → elect Patent Box → enjoy 10% effective CT on the resulting commercial profits.
    When should I elect into Patent Box?+
    Within 2 YEARS OF THE END of the accounting period for which the election is to apply, prospective only, can't retroactively claim beyond that window. Most companies elect in the FIRST YEAR they have qualifying patent income (after a patent grants + revenue starts flowing). The election applies to ALL qualifying IP held by the company, you can't pick which patents to elect for. Once elected, the regime applies until you elect out (which is allowed but creates 5-year lockout from re-election). For companies with multiple patents at different commercial stages, time the election to maximise benefit on the first commercially material patent grant. Documentation requirements are substantial: track every patent's R&D cost composition + every revenue stream's attribution to specific patents + nexus calculations per IP, typically done with specialist tax adviser support.

    Last reviewed: